Article Correctness Is Author's Responsibility: FDA Accepts NDA Resubmission for Oral Cladribine in Relapsing MS

The article below may contain offensive and/or incorrect content.

The NDA resubmission is in response to the FDA's Complete Response Letter issued in 2011 which requested an improved understanding of the safety risks and overall benefit-risk profile.